PARP 저해제 바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 서비스별, 용도별, 지역별, 부문별 예측(2024-2030년)

PARP Inhibitor Biomarkers Market Growth & Trends:

The global PARP inhibitor biomarkers market size is anticipated to reach USD 1,602.10 million by 2030 and is projected to grow at a CAGR of 8.54% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of breast cancer is a significant factor for market expansion in the PARP Inhibitors biomarkers sector. According to the WHO article published in 2022, increasing prevalence of cancer cases, with an estimated 20 million new cases of 9.7 million deaths reported. Despite advancements, the fight against cancer remains tough, with an estimated 53.5 million individuals surviving within 5 years of diagnosis. Moreover, Female breast cancer emerges as a significant concern, ranking second in global cases at 2.3 million (11.6%), accounting for 670,000 deaths (6.9%). Especially it stands as the most widespread among women across 157 out of 185 countries surveyed.

Advancements in genomic technologies have significantly contributed to developing and refining PARP inhibitor biomarkers. According to the NCBI article published in August 2021, these advancements have enabled researchers to identify and validate biomarkers that predict patients' response to PARP inhibitors, thereby facilitating personalized treatment strategies. A study developed a 3D functional assay to identify biomarkers predictive of the response to poly-ADP ribose polymerase inhibitors (PARPis) in high-grade serous ovarian cancer (HGSOC) patients. This approach allowed for a more accurate and comprehensive understanding of how cells respond to PARP inhibitors in a physiologically relevant environment.

The increasing expenditure for treatment and management fuels the market growth. According to the articleBioMed Central Ltd published in September 2022, particularly for breast and ovarian cancer, is a major issue influenced by several factors, including the stage of diagnosis, the specific treatments used, and the overall healthcare costs associated with cancer care. The provided sources offer insights into the financial burden of treatments and the factors contributing to their rising expenditure. Breast and ovarian cancer patients face significant financial burdens throughout their treatment journey.

The financial burden of oncology care can be significant and vary widely based on diagnosis stage and treatment methods. Patients diagnosed in later stages generally incur higher annual and cumulative healthcare expenses compared to those diagnosed earlier. This trend is evident in the data, showing notably higher mean annual and cumulative healthcare costs for patients diagnosed at later stages. The considerable rise in cumulative costs, particularly for stage IV diagnoses across various cancer types such as ovarian, emphasizes the critical importance of early detection. Timely diagnosis allows more effective treatment and also contributes to better patient outcomes and reduced healthcare expenditures further propelling market growth.

PARP Inhibitor Biomarkers Market Report Highlights:

• The kits segment led the market with the largest revenue share of 65.35% in 2023. It is due to attributed of rising the awareness regarding effective diagnostics solutions
• The assays segment is anticipated to grow at the fastest CAGR during the forecast period, owing to being a crucial component for developing and validating PARP inhibitor biomarkers, enabling researchers and clinicians to measure these biomarkers' levels in biological samples accurately
• Based on services, the BRCA1 & 2 testing segment led the market with the largest revenue share of 43.54% in 2023, due to its critical role in treatment. The rise in importance of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers has further boosted its significance
• In terms of application, the breast cancer segment led the market with the largest revenue share of 48.42% in 2023. The ovarian cancer segment is anticipated to grow at the fastest CAGR during the forecast period
• North America dominated the market with the revenue share of 43.95% in 2023, owing to factors such as advancement in genomic technologies, high purchasing power parity, government support for quality healthcare, and funding for development of novel diagnostics

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Services
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Services outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. PARP Inhibitor Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of breast cancer
    • 3.2.1.2. Advancements in genomic technologies
    • 3.2.1.3. Rising expenditure for cancer treatment
    • 3.2.1.4. Growing adoption of personalized medicine and precision therapy
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of PARP inhibitor biomarker test kits and assays
    • 3.2.2.2. Limited awareness and understanding of PARP inhibitors biomarkers
• 3.3. PARP Inhibitor Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. PARP Inhibitor Biomarkers Market: Product Estimates & Trend Analysis

• 4.1. PARP Inhibitor Biomarkers Market: Product Dashboard
• 4.2. PARP Inhibitor Biomarkers Market: Product Movement Analysis
• 4.3. PARP Inhibitor Biomarkers Market by Product Revenue
• 4.4. Kits
  • 4.4.1. Kits Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Assays
  • 4.5.1. Assays Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. PARP Inhibitor Biomarkers Market: Services Estimates & Trend Analysis

• 5.1. PARP Inhibitor Biomarkers Market: Services Dashboard
• 5.2. PARP Inhibitor Biomarkers Market: Services Movement Analysis
• 5.3. PARP Inhibitor Biomarkers Market by Services Revenue
• 5.4. BRCA 1 & 2 Testing
  • 5.4.1. BRCA 1 & 2 Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. HRD Testing
  • 5.5.1. HRD Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. HRR Testing
  • 5.6.1. HRR Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. PARP Inhibitor Biomarkers Market: Application Estimates & Trend Analysis

• 6.1. PARP Inhibitor Biomarkers Market: Application Dashboard
• 6.2. PARP Inhibitor Biomarkers Market: Application Movement Analysis
• 6.3. PARP Inhibitor Biomarkers Market by Application Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Ovarian Cancer
  • 6.5.1. Ovarian Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. PARP Inhibitor Biomarkers Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. North America
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. Mexico
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Argentina
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Myriad Genetics, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Ambry Genetics
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Thermo Fisher Scientific Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Illumina, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. CENTOGENE N.V.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Amoy Diagnostics Co., Ltd.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Invitae Corporation
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. NeoGenomics Laboratories.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. QIAGEN
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Agilent Technologies, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives